UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 22, 2026
IMMIX BIOPHARMA, INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 001-41159 | 45-4869378 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
11400 West Olympic Blvd., Suite 200
Los Angeles, CA 90064
(Address of principal executive offices)
(310) 651-8041
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(b)of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value of $0.0001 per share | IMMX | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 22, 2026, at the 2026 Annual Meeting of stockholders (the “Annual Meeting”) of Immix Biopharma, Inc. (the “Company”), the Company’s stockholders voted on the following two (2) proposals and votes were cast as described below. These matters are described in more detail in the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 6, 2026.
The final results of voting on each proposal presented at the Annual Meeting are set forth below.
| 1. | Proposal 1 — Election of Directors Proposal
The stockholders elected each of the individuals listed below to serve as a director of the Company until the next annual meeting of stockholders and until such director’s successor is duly elected and qualified. The results of the voting for this proposal were as follows: |
| For | Withheld | Broker Non-Votes | ||||||||||
| Ilya Rachman | 35,738,887 | 121,893 | 6,445,684 | |||||||||
| Gabriel Morris | 34,353,302 | 1,507,479 | 6,445,683 | |||||||||
| Jason Hsu | 35,844,812 | 15,969 | 6,445,683 | |||||||||
| Magda Marquet | 35,731,188 | 129,592 | 6,445,684 | |||||||||
| Helen C. Adams | 35,677,258 | 183,522 | 6,445,684 | |||||||||
| Carey Ng | 35,840,860 | 19,921 | 6,445,683 | |||||||||
| Jane Buchan | 35,731,346 | 129,434 | 6,445,684 | |||||||||
| Yekaterina Chudnovsky | 35,749,420 | 111,360 | 6,445,684 | |||||||||
| Nancy Chang | 35,744,455 | 116,325 | 6,445,684 | |||||||||
| 2. | Proposal No. 2 — Ratification of Auditors Proposal
The stockholders ratified the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of the voting for this proposal were as follows: |
| For | Against | Abstentions | Broker Non-Votes | |||||||||
| 42,276,496 | 11,526 | 18,442 | — | |||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Immix Biopharma, Inc. | |
| Dated: May 29, 2026 | /s/ Ilya Rachman |
| Ilya Rachman, M.D., Ph.D. | |
| Chief Executive Officer |